Thanks in part to swift COVID-19 response and relatively low infection rates, more sites and sponsors are looking at the region to locate their studies.
The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.
Hospira has invested 15m AUD ($14m) in a Victoria injectables plant it says will continue to make drugs for export despite the economic downturn and strong Australian dollar.
Operations will continue and may even be enhanced at DSM’s Australian taxpayer-funded biologics plant following a merger with Patheon, the Queensland Government says.
GlaxoSmithKline (GSK) says some manufacturing from the shuttering of an Australian packaging site will be picked up by Aspen and local third-party contractors.
With backing from the Australian Government, DSM has opened a mammalian cell culture operation to fuel the growing demand in the Asia-Pacific biologics market.
The Australian Government has announced a plan to improve how the TGA communicates with stakeholders just days after criticism about plans to increase fees.
Australia's clinical trial industry is taking steps to promote
itself further on the world stage, along with the forging of closer
ties with the budding Asia-Pacific region.
As the Asia-Pacific continues to be a hotspot for clinical trials
activity, e-clinical provider ClinPhone has opened its first office
in the region in the hope of gaining a head start.
The creditors of Australian over-the-counter medicines and vitamins
manufacturer Pan Pharmaceuticals have rejected a rescue bid for the
company at a meeting held last week. Another meeting is due to be
held later today.
